The first glucose concentration peak was seen to be larger than its corresponding pre-insulin baseline peak, and we termed this behavior “rebound hyperglycemia.” Furthermore, the first glucose concentration trough after the injection was significantly lower than the corresponding baseline trough. The gene discussed is INS; the disease is Hyperglycemia.